The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Sponsor
Northwell Health
Study ID
NCT02768220
Phase
PHASE4
Status
Withdrawn

Conditions

  • Advanced Glycation End Products
  • Diabetes
  • SGLT-2 Inhibitors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • empagliflozin — DRUG
    Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
  • linagliptin — DRUG
    Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels

Study Details

Single-center open-label multiple dose randomized two period cross-over study to examine Advanced Glycation End Product (AGE) levels in human subjects pre and post empagliflozin administration.

Key Dates

Start date
Dec 1, 2017
Status verified
Feb 2018
Primary completion
Aug 31, 2018
Completion
Dec 31, 2018

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Linagliptin
    Eligible patients were randomized to receive linagliptin 5mg daily for 30 days.
  • Experimental: Empagliflozin
    Eligible patients were randomized empagliflozin 25mg daily for 30 days.

Primary Outcome Measure

Change in AGE levels [ Time Frame: 30 days ]

Related Studies